A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC 742460) in Children With Relapsed/Refractory Solid Tumors

Trial Profile

A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC 742460) in Children With Relapsed/Refractory Solid Tumors

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2015

At a glance

  • Drugs Cixutumumab (Primary)
  • Indications Adenocarcinoma; Brain cancer; Ewing's sarcoma; Liver cancer; Neuroblastoma; Neuroectodermal tumours; Osteosarcoma; Retinoblastoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Synovial sarcoma; Wilms' tumour
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 29 Mar 2015 Protocol has been amended to change in incl/excl, treatment arms and patient number.
    • 01 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 04 Sep 2013 Planned End Date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top